NDAORALSUSPENSION, EXTENDED RELEASE
Approved
May 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
ONYDA XR (clonidine hydrochloride) by Teva is 2 -adrenergic receptors in the brain. First approved in 2024.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ONYDA XR is a once-daily extended-release oral suspension formulation of clonidine hydrochloride, an alpha-2 adrenergic receptor agonist approved by FDA in May 2024. It treats ADHD through central nervous system mechanisms that remain incompletely understood; clonidine is not a stimulant. The product represents a novel delivery format for an established therapeutic agent in a high-prevalence psychiatric indication.
Growth14.8 years to LOE
Early-stage product in rapid growth phase with emerging market opportunity; commercial teams are building market infrastructure and establishing payer relationships.
Mechanism of Action
2 -adrenergic receptors in the brain. Clonidine is not a central nervous system stimulant. The mechanism of action of clonidine in ADHD is not known.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ONYDA XR represents a growth-stage opportunity for pharma professionals seeking launch-phase commercial experience in a high-prevalence therapeutic area. Current low linked job count reflects recent approval status; career trajectory will accelerate as market penetration increases and Teva expands its commercial infrastructure.
Brand ManagerMedical Science Liaison
Worked on ONYDA XR at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.